SeaStar Medical reports 2023 net loss $26.2M; first FDA approval for Quelimmune pediatric device

SeaStar Medical Holding Corp

2024-Q1 EPS reported -$0.19

Net loss $26.2M ($1.21/share) in 2023 vs $12.2M ($1.48/share) in 2022; cash $176K at Dec 31, 2023.
FDA approved SCD-Pediatric (Quelimmune) in Feb 2024 for pediatric AKI with sepsis; distribution via Nuwellis.
NEUTRALIZE-AKI adult trial enrolled 24 subjects; interim analysis expected H2 2024 after 100 reach 90-day endpoint.
Appointed David A. Green as CFO in Jan 2024; completed $9.0M registered direct offering same month.
Restated 2022 financials (non-cash items); minimal impact on cash/operations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SeaStar Medical Holding Corp reported financial results for the 12 months ended December 31, 2023.

Period: the 12 months ended December 31, 2023
Result: reported results

Exact text from the filing

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update DENVER (April 17, 2024) – SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0000929638-24-001513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.